Cerity Partners
ALDX icon

Cerity Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Cerity Partners’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137K Buy
81,223
+30,174
+59% +$132K ﹤0.01% 2972
2025
Q4 		$264K Sell
51,049
-9,307
-15% -$47.8K ﹤0.01% 2481
2025
Q3 		$315K Buy
60,356
+23,779
+65% +$124K ﹤0.01% 2247
2025
Q2 		$140K Buy
+36,577
New +$94.6K ﹤0.01% 2431

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cerity Partners's ALDX Position: Q1 2026 in Review

Cerity Partners increased its Aldeyra Therapeutics (ALDX) stake by 59% in Q1 2026, buying an estimated $132K and bringing the position to 81,223 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #2972.

Cerity Partners first reported a position in ALDX in Q2 2025 and has held it in 4 quarters since. The position peaked at $315K in Q3 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Cerity Partners held 81,223 shares of Aldeyra Therapeutics worth $137K as of Q1 2026.
  • Cerity Partners bought 30,174 Aldeyra Therapeutics shares in Q1 2026, an estimated $132K.
  • Aldeyra Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2972 holding.
  • Cerity Partners first reported a position in Aldeyra Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Cerity Partners's Aldeyra Therapeutics position peaked at $315K in Q3 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.